The Shy-Drager syndrome, also known as multiple system atrophy with autonomic failure, is a degenerative disorder of the nervous system which affects the central pathways involved in normal voluntary movement and the autonomic nervous system. 1 There are no distinctive biochemical disturbances but a severe depletion of the brain catecholamines, dopamine and noradrenaline, occurs and central cholinergic systems are also affected.2 In contrast to Parkinson's disease, however, where similar abnormalities occur, dopamine replacement therapy has proved disappointing. Temporary improvement has been reported in a few patients with both levodopa and the dopaminergic agonist, bromocriptine, but unresponsiveness even to large doses is more common. A more complete destruction of dopaminergic neurones in the substantia nigra might offer one explanation for this disparity as both levodopa and bromocriptine require an intact presynaptic neuronal apparatus to produce their pharmacological effects.
Lisuride hydrogen maleate is a semi-synthetic ergolene derived from d-isolysergic acid. It is a powerful antagonist of 5-hydroxytryptamine and in common with some other ergot alkaloids, it possesses dopamine receptor stimulating properties. For example, it provokes stereotypy in rodents, reverses reserpine-induced catalepsy and hypothermia3 and causes contralateral rotation in rats with unilateral destruction of the nigro-striatal dopaminergic pathway.4 Lisuride increases brain dopamine concentration, reduces brain dopamine turnover5 and is a potent suppressor of prolactin release in animals and man.6 One important difference between lisuride and the structurally related bromocriptine is that the former's behavioural and biochemical effects are not abolished by inhibition of tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine.3 This suggests that lisuride acts as a direct postsynaptic dopaminergic agonist and it could, therefore, have beneficial effects even in the total absence of dopaminergic neurones. This justified a trial of lisuride in patients with multisystem degeneration and autonomic failure.
Patients and methods
Seven patients with multi-system degeneration and autonomic failure agreed to participate in a controlled A J Lees and Roger Bannister trial of lisuride hydrogen maleate to be carried out in hospital. All of them had Parkinsonian features and postural hypotension with abnormalities of their cardiovascular reflexes. Severe bradykinesia and rigidity were present in patients Nos 1, 2, 3, 5, 6, and 7 and three of the patients also had a coarse (4-7 Hz) tremor at rest (patients Nos 1, 2, 7). The results of levodopa therapy in combination with a peripheral dopa decarboxylase inhibitor in the patients are shown in the table. After informed consent all levodopa preparations were withdrawn; only one of the three patients still receiving them deteriorated appreciably (patient No 6). Patients Nos 1, 5 and 7 had also taken bromocriptine without benefit and profound aggravation of orthostatic hypotension had occurred in two (patients Nos 5 and 7).
For ethical reasons patient No 6 was given lisuride in an open fashion as he became severely incapacitated on withdrawal of levodopa. The remainder of the patients took part in a randomised double-blind cross-over trial using a placebo indistinguishable from lisuride. Treatment was begun with an initial dose of 0-2 mg a day after supper and after three days this was increased to 0-2 mg every 8 hours following meals. After this daily increments of 0-6 mg in divided dosage were made every three days up to optimum tolerated levels or an arbitrary maximum daily dosage of 5 mg. The patients were maintained on maximum doses for a minimum of 7 days and each phase of the trial lasted for 6 weeks. If toxic side-effects occurred the daily dose was reduced by 0-6 mg and the patients were kept at that level of drug intake until the end of the trial.
Patients were evaluated twice a week by the same assessor using a modified Columbia University scale (4-point disability rating system).7 Fifteen parameters were used to give a maximum total disability score of 60. Erect and supine blood pressure recordings were made at six-hourly intervals. For statistical analysis the last three disability scores on active and placebo medication, were used together with mean lying and standing blood pressures taken over the last three days of each phase of the trial.
Results
The mean dose of lisuride was 2-4 mg (0 6-5 0 mg) daily but only patient No It is possible that patient No 7 was suffering from Parkinsonism with autonomic failure rather than the Shy-Drager syndrome and it is of interest that she was one of the two patients who derived marked initial benefit from levodopa. The effects of levodopa therapy on the 21 patients in the medical literature with bradykinetic-rigid syndromes found at necropsy to be due to striatonigral degeneration are shown in the table.2 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Only one patient22 had derived sustained worthwhile improvement and at the price of dyskinesias, but initial benefit lasting up to 6 months occurred in a further six. Eight of these 21 patients also had autonomic failure (Shy-Drager syndrome)2 12 17 20 21 and in only two of these17 20 did transient benefit in extrapyramidal features occur. Clinical studies also confirm the poor response of the Shy-Drager syndrome to levodopa,23 although two patients with olivo-ponto-cerebellar degeneration improved. 24 Results with bromocriptine have been similar25-27 with temporary benefit occurring in occasional patients. There is only one histologically confirmed case of Parkinsonism with autonomic failure in the literature who received levodopa. 21 In this patient a dose of 3 0 g levodopa per day produced a marked increase in postural hypotension, as occurred in our patient No 7.
The therapeutic effects of lisuride in this study were extremely disappointing; modest benefit occurring only in patient No 7. Patient No 6 who was the only one benefiting from levodopa, derived no benefit from lisuride at high dosage. Damage to post-synaptic dopamine receptors is known to occur in the Shy-Drager syndrome and this may be the explanation for the lack of improvement. 28 Lisuride had no significant effects on postural hypotension although in two patients (patients Nos 4 and 7) a modest elevation occurred. It was of interest that patient No 7 had experienced syncopal attacks with levodopa and bromocriptine. A rise in standing blood pressure has also occasionally been reported with levodopa23 29 
